|
[1]
|
Younossi, Z., Anstee, Q.M., Marietti, M., Hardy, T., Henry, L., Eslam, M., et al. (2017) Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention. Nature Reviews Gastroenterology & Hepatology, 15, 11-20. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Fang, J., Celton-Morizur, S. and Desdouets, C. (2023) NAFLD-Related HCC: Focus on the Latest Relevant Preclinical Models. Cancers, 15, Article No. 3723. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Alencar, R.S.d.S.M., Oliveira, C.P., Chagas, A.L., Fonseca, L.G.d., Maccali, C., Saud, L.R.d.C., et al. (2022) Hepatocellular Carcinoma (HCC) in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Screening, Treatment and Survival Analysis in a Brazilian Series. Clinics, 77, Article ID: 100097. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Ioannou, G.N. (2016) The Role of Cholesterol in the Pathogenesis of Nash. Trends in Endocrinology & Metabolism, 27, 84-95. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Horn, C.L., Morales., A.L., Savard, C., Farrell, G.C. and Ioannou, G.N. (2021) Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH. Hepatology Communications, 6, 12-35. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Zhao, Z., Zhong, L., Li, P., He, K., Qiu, C., Zhao, L., et al. (2020) Cholesterol Impairs Hepatocyte Lysosomal Function Causing M1 Polarization of Macrophages via Exosomal miR-122-5p. Experimental Cell Research, 387, Article ID: 111738. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Musso, G., Cassader, M., Paschetta, E. and Gambino, R. (2018) Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. Gastroenterology, 155, 282-302.e8. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Guo, X., Yin, X., Liu, Z. and Wang, J. (2022) Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. International Journal of Molecular Sciences, 23, Article No. 15489. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Lindén, D. and Romeo, S. (2023) Therapeutic Opportunities for the Treatment of NASH with Genetically Validated Targets. Journal of Hepatology, 79, 1056-1064. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Wang, P., Wu, C., Li, Y., Gong, Y. and Shen, N. (2020) PNPLA3 Rs738409 Is Not Associated with the Risk of Hepatocellular Carcinoma and Persistent Infection of Hepatitis B Virus (HBV) in HBV-Related Subjects: A Case-Control Study and Meta-Analysis on Asians. Gene, 742, Article ID: 144585. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Seko, Y., Lin, H., Wong, V.W. and Okanoue, T. (2024) Impact of pnpla3 in Lean Individuals and in Cryptogenic Steatotic Liver Disease. Liver International, 45, e16164. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Sunami, Y., Rebelo, A. and Kleeff, J. (2021) Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer. Cancers, 13, Article No. 4391. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Volynets, V., Küper, M.A., Strahl, S., Maier, I.B., Spruss, A., Wagnerberger, S., et al. (2012) Nutrition, Intestinal Permeability, and Blood Ethanol Levels Are Altered in Patients with Nonalcoholic Fatty Liver Disease (NAFLD). Digestive Diseases and Sciences, 57, 1932-1941. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Behary, J., Amorim, N., Jiang, X., Raposo, A., Gong, L., McGovern, E., et al. (2021) Gut Microbiota Impact on the Peripheral Immune Response in Non-Alcoholic Fatty Liver Disease Related Hepatocellular Carcinoma. Nature Communications, 12, Article No. 187. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M.P. and Gastaldelli, A. (2020) Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. International Journal of Molecular Sciences, 21, Article No. 5820. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Cavalcante, L.N., Dezan, M.G.F., Paz, C.L.d.S.L. and Lyra, A.C. (2022) Risk Factors for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. Arquivos de Gastroenterologia, 59, 540-548. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Nassir, F. (2022) NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules, 12, Article No. 824. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Sheka, A.C., Adeyi, O., Thompson, J., Hameed, B., Crawford, P.A. and Ikramuddin, S. (2020) Nonalcoholic Steatohepatitis: A Review. JAMA, 323, 1175-1183.
|
|
[19]
|
Yuan, C., Zhang, C., Geng, X., Feng, C., Su, Y., Wu, Y., et al. (2024) Associations of an Overall Healthy Lifestyle with the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease. BMC Public Health, 24, Article No. 3264. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Zhang, C. and Yang, M. (2021) Current Options and Future Directions for NAFLD and NASH Treatment. International Journal of Molecular Sciences, 22, Article No. 7571. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Xu, X., Poulsen, K.L., Wu, L., Liu, S., Miyata, T., Song, Q., et al. (2022) Targeted Therapeutics and Novel Signaling Pathways in Non-Alcohol-Associated Fatty Liver/Steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy, 7, Article No. 287. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Parola, M. and Pinzani, M. (2024) Liver Fibrosis in NAFLD/NASH: From Pathophysiology towards Diagnostic and Therapeutic Strategies. Molecular Aspects of Medicine, 95, Article ID: 101231. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Raza, S. (2021) Current Treatment Paradigms and Emerging Therapies for NAFLD/NASH. Frontiers in Bioscience, 26, 206-237. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Wei, S., Wang, L., Evans, P.C. and Xu, S. (2024) NAFLD and NASH: Etiology, Targets and Emerging Therapies. Drug Discovery Today, 29, Article ID: 103910. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., et al. (2024) EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Journal of Hepatology, 81, 492-542. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Muthiah, M.D. and Sanyal, A.J. (2020) Current Management of Non‐Alcoholic Steatohepatitis. Liver International, 40, 89-95. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Foerster, F., Gairing, S.J., Müller, L. and Galle, P.R. (2022) NAFLD-Driven HCC: Safety and Efficacy of Current and Emerging Treatment Options. Journal of Hepatology, 76, 446-457. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Pal Chaudhary, S., Reyes, S., Chase, M.L., Govindan, A., Zhao, L., Luther, J., et al. (2023) Resection of NAFLD/NASH-Related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC due to Other Etiologies. The Oncologist, 28, 341-350. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Velliou, R., Legaki, A., Nikolakopoulou, P., Vlachogiannis, N.I. and Chatzigeorgiou, A. (2023) Liver Endothelial Cells in NAFLD and Transition to NASH and HCC. Cellular and Molecular Life Sciences, 80, Article No. 314. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Falette Puisieux, M., Pellat, A., Assaf, A., Ginestet, C., Brezault, C., Dhooge, M., et al. (2022) Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. Cancers, 14, Article No. 2357. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Shi, Y., Taherifard, E., Saeed, A. and Saeed, A. (2024) MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options. Current Issues in Molecular Biology, 46, 5965-5983. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版) [J]. 协和医学杂志, 2024, 15(3): 532-559.
|
|
[33]
|
Sadler, E.M., Mehta, N., Bhat, M., Ghanekar, A., Greig, P.D., Grant, D.R., et al. (2018) Liver Transplantation for NASH-Related Hepatocellular Carcinoma versus Non-NASH Etiologies of Hepatocellular Carcinoma. Transplantation, 102, 640-647. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Conci, S., Cipriani, F., Donadon, M., Marchitelli, I., Ardito, F., Famularo, S., et al. (2022) Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) Related HCC: Propensity Case-Matched Analysis with Viral-and Alcohol-Related HCC. European Journal of Surgical Oncology, 48, 103-112. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Rajendran, L., Murillo Perez, C.F., Ivanics, T., Claasen, M.P.A.W., Hansen, B.E., Wallace, D., et al. (2023) Outcomes of Liver Transplantation in Non-Alcoholic Steatohepatitis (NASH) versus Non-Nash Associated Hepatocellular Carcinoma. HPB, 25, 556-567. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Khalid, M., Likhitsup, A. and Parikh, N.D. (2025) Embolic and Ablative Therapy for Hepatocellular Carcinoma. Clinics in Liver Disease, 29, 87-103. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Hwang, S.Y., Danpanichkul, P., Agopian, V., Mehta, N., Parikh, N.D., Abou-Alfa, G.K., et al. (2025) Hepatocellular Carcinoma: Updates on Epidemiology, Surveillance, Diagnosis and Treatment. Clinical and Molecular Hepatology, 31, S228-S254. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Pfister, D., Núñez, N.G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., et al. (2021) NASH Limits Anti-Tumour Surveillance in Immunotherapy-Treated HCC. Nature, 592, 450-456. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Pinter, M., Pinato, D.J., Ramadori, P. and Heikenwalder, M. (2022) NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy. Clinical Cancer Research, 29, 513-520. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Guo, Z., Yao, Z., Huang, B., Wu, D., Li, Y., Chen, X., et al. (2024) MAFLD-Related Hepatocellular Carcinoma: Exploring the Potent Combination of Immunotherapy and Molecular Targeted Therapy. International Immunopharmacology, 140, Article ID: 112821. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Gutiérrez-Cuevas, J., Lucano-Landeros, S., López-Cifuentes, D., Santos, A. and Armendariz-Borunda, J. (2022) Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. Cancers, 15, Article No. 23. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Younossi, Z.M., Kalligeros, M. and Henry, L. (2025) Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease. Clinical and Molecular Hepatology, 31, S32-S50. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Khare, T., Liu, K., Chilambe, L.O. and Khare, S. (2025) NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials. International Journal of Molecular Sciences, 26, Article No. 306. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Wu, G., Bajestani, N., Pracha, N., Chen, C. and Makary, M.S. (2024) Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances. Cancers, 16, Article No. 3933. [Google Scholar] [CrossRef] [PubMed]
|